Cryptococcosis¶
Chapter 221 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Cryptococcosis is caused by Cryptococcus neoformans and C. gattii, now classified as species complexes.
- Diagnosis relies on detection of cryptococcal antigen (CRAg) in CSF/blood, India ink staining, and culture.
- Treatment varies by severity: fluconazole for mild cases, amphotericin B + 5-FC for severe CNS involvement.
1. DEFINITION & OVERVIEW¶
Cryptococcosis is a fungal infection caused by Cryptococcus neoformans and C. gattii, now recognized as species complexes. It primarily affects immunocompromised individuals, particularly those with HIV/AIDS. The disease can present as pulmonary, meningeal, or disseminated infections.
Cryptococcal Antigen Detection in CSF and Blood¶
| Test Type | Sensitivity | Specificity | Use Case |
|---|---|---|---|
| Cryptococcal Antigen (CRAg) Assay | 95–100% | 95–100% | Diagnosis of CNS and systemic infections |
| India Ink Stain | 70–80% | 95–100% | Rapid detection of cryptococcal cells in CSF |
| Culture | 80–90% | 100% | Confirmatory test for cryptococcal species identification |
1.1 Etiology¶
Cryptococcus species are yeast-like fungi. C. neoformans (var. grubii/serotype A and var. neoformans/serotype D) and C. gattii (serotype B/C) are the main pathogens. These fungi form a polysaccharide capsule, which contributes to virulence.
1.2 Pathogenesis¶
Inhalation of cryptococcal cells/spores leads to infection. The capsule prevents phagocytosis, and melanin production enhances survival. Virulence factors include polysaccharide capsule, melanin, and enzymes like phospholipase and urease.
2. EPIDEMIOLOGY¶
Cryptococcosis was rare until the mid-20th century due to immunosuppression. Global burden estimated at ~1 million cases annually, with >600,000 deaths. HIV/AIDS remains the primary risk factor, with ~10% of HIV-infected individuals developing cryptococcal meningitis.
2.1 Risk Factors¶
Immunosuppression (HIV/AIDS, organ transplant, malignancy), diabetes, chronic lung disease, and corticosteroid use. C. gattii is more common in tropical regions and is not typically associated with immune deficiency.
2.2 Demographics¶
Most cases occur in sub-Saharan Africa and Southeast Asia. In HIV-infected individuals, up to one-third with AIDS develop cryptococcosis. Mortality rates range from 5–13%, often due to ARDS or CNS complications.
3. CLINICAL FEATURES¶
Clinical manifestations depend on infection site. Pulmonary disease presents with cough, chest pain, and radiographic nodules. CNS involvement (meningitis) causes headache, fever, and neurologic deficits. Disseminated disease may involve skin, bones, or visceral organs.
3.1 CNS Involvement¶
Chronic meningitis with headache, fever, lethargy, and cranial nerve palsies. Meningismus may be absent. Subacute dementia or depression may occur in immunocompetent patients.
3.2 Pulmonary Involvement¶
Cough, sputum production, and chest pain. Radiographic findings include nodules, infiltrates, or cryptococcomas (granulomatous masses).
4. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires detection of cryptococcal antigen, fungal cells, or culture. CSF analysis is critical for CNS disease. Serum and CSF antigen testing are highly sensitive and specific.
Cryptococcal Antigen Detection in CSF and Blood¶
| Test Type | Sensitivity | Specificity | Use Case |
|---|---|---|---|
| Cryptococcal Antigen (CRAg) Assay | 95–100% | 95–100% | Diagnosis of CNS and systemic infections |
| India Ink Stain | 70–80% | 95–100% | Rapid detection of cryptococcal cells in CSF |
| Culture | 80–90% | 100% | Confirmatory test for cryptococcal species identification |
4.1 Diagnostic Criteria¶
CSF findings: elevated opening pressure, pleocytosis, low glucose, and high protein. Cryptococcal antigen detection in CSF or serum is the gold standard. India ink staining of CSF may reveal encapsulated yeast cells.
4.2 Imaging¶
Chest X-ray or CT may show pulmonary nodules or masses. MRI is preferred for CNS involvement to detect cryptococcomas or meningeal enhancement.
5. MANAGEMENT & TREATMENT¶
Treatment depends on disease severity. Mild pulmonary disease is managed with fluconazole. Severe CNS or disseminated disease requires combination therapy with amphotericin B and 5-flucytosine. Long-term suppressive therapy may be needed for immunocompromised patients.
Treatment Regimens for Cryptococcosis¶
| Patient Population | Therapy | Duration |
|---|---|---|
| Immunocompetent, Mild Pulmonary | Fluconazole 400 mg/day | 6–12 months |
| Immunocompromised, CNS Involvement | Lipid AmB + 5-FC + Fluconazole | 2–4 weeks induction, 1 year maintenance |
| Pregnant Women | Lipid AmB (6–8 weeks) | Avoid azoles |
5.1 Mild Pulmonary Cryptococcosis¶
Fluconazole 400 mg daily for 6–12 months. Avoid azoles in pregnant women. Monitor for drug interactions and liver toxicity.
5.2 Severe CNS Involvement¶
Induction: Lipid amphotericin B (3–5 mg/kg/day) + 5-FC (25 mg/kg q8h) for 2–4 weeks. Consolidation: Voriconazole or fluconazole. Maintenance: Fluconazole 200–400 mg daily for 1 year.
5.3 Pregnancy Considerations¶
Lipid amphotericin B is preferred (6–8 weeks). Avoid azole antifungals due to teratogenic risk. Fluconazole may cause fetal malformations.
6. PROGNOSIS & COMPLICATIONS¶
Mortality rates range from 5–13%, primarily due to ARDS or CNS complications. Long-term sequelae include neurologic deficits, pulmonary fibrosis, and recurrent infections. Immunosuppressed patients require prolonged suppressive therapy.
6.1 Complications¶
Cerebral cryptococcomas, hydrocephalus, and meningitis. Pulmonary fibrosis and chronic cough may persist after recovery.
6.2 Monitoring¶
Regular follow-up with CSF antigen testing and imaging to detect relapse. Adjust antifungal therapy based on immune status and response.
7. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid azoles; use lipid amphotericin B. HIV-infected patients require ART and antifungal prophylaxis. In resource-limited regions, point-of-care CRAg testing is critical for early diagnosis.
7.1 HIV-Associated Cryptococcosis¶
Most cases occur in HIV/AIDS patients with CD4+ <200/ µ L. ART reduces incidence but does not eliminate risk. Prophylaxis with fluconazole is recommended for high-risk patients.
7.2 Resource-Limited Settings¶
Point-of-care CRAg testing is essential for rapid diagnosis. Fluconazole is preferred due to cost-effectiveness and availability.
8. KEY POINTS & CLINICAL PEARLS¶
- Cryptococcosis is a leading cause of fungal meningitis in immunocompromised patients. 2. CRAg testing is the most sensitive diagnostic tool. 3. Lipid amphotericin B is preferred for CNS involvement. 4. Long-term suppressive therapy is required for HIV patients. 5. Avoid azoles in pregnancy due to teratogenic risk.